Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Celecoxib in Completely Resected, High-Risk (pN1-2) NSCLC
NCT00211952Phase 3Suspended
- Sponsor
- Medical University of Gdańsk
- Start
- Mar 2004
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Celecoxib with Placebo (2 arms). Primary endpoint: Relapse-Free Survival. Started Mar 2004; status: suspended.
02
Drugs
celecoxib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00211952.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00211952.